Adverum Biotechnologies Ownership
| ADVM Stock | USD 5.10 0.50 8.93% |
Shares in Circulation | First Issued 2014-09-30 | Previous Quarter 21 M | Current Value 21 M | Avarage Shares Outstanding 7.4 M | Quarterly Volatility 4.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Adverum |
Adverum Stock Ownership Analysis
About 13.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.74. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adverum Biotechnologies recorded a loss per share of 5.95. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 21st of March 2024. Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Adverum Biotechnlgs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 188 people. For more info on Adverum Biotechnologies please contact Laurent Fischer at 650 656 9323 or go to https://adverum.com.Besides selling stocks to institutional investors, Adverum Biotechnologies also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Adverum Biotechnologies' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Adverum Biotechnologies' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Adverum Biotechnologies Quarterly Liabilities And Stockholders Equity |
|
Adverum Biotechnologies Insider Trades History
About 13.0% of Adverum Biotechnologies are currently held by insiders. Unlike Adverum Biotechnologies' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Adverum Biotechnologies' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Adverum Biotechnologies' insider trades
Adverum Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adverum Biotechnologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adverum Biotechnologies backward and forwards among themselves. Adverum Biotechnologies' institutional investor refers to the entity that pools money to purchase Adverum Biotechnologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-12-31 | 311 K | Soleus Capital Management, L.p. | 2024-12-31 | 287.2 K | Regeneron Pharmaceuticals Inc | 2024-12-31 | 180.9 K | Nuveen Asset Management, Llc | 2024-12-31 | 172.4 K | Northern Trust Corp | 2024-12-31 | 152.6 K | Citadel Advisors Llc | 2024-12-31 | 149.1 K | Renaissance Technologies Corp | 2024-12-31 | 129.6 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 114.8 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 98 K | Bml Capital Management Llc | 2024-12-31 | 2.3 M | Tcg Crossover Management, Llc | 2024-12-31 | 1.8 M |
Adverum Biotechnologies Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adverum Biotechnologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adverum Biotechnologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adverum Biotechnologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adverum Biotechnologies Outstanding Bonds
Adverum Biotechnologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Adverum Biotechnologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Adverum bonds can be classified according to their maturity, which is the date when Adverum Biotechnologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US00775PAA57 Corp BondUS00775PAA57 | View | |
| AERCAP IRELAND CAP Corp BondUS00774MAG06 | View | |
| AERCAP IRELAND CAP Corp BondUS00774MAE57 | View | |
| AERCAP IRELAND CAP Corp BondUS00774MAB19 | View | |
| AER 385 29 OCT 41 Corp BondUS00774MAZ86 | View | |
| AER 33 30 JAN 32 Corp BondUS00774MAX39 | View | |
| AER 34 29 OCT 33 Corp BondUS00774MAY12 | View |
Adverum Biotechnologies Corporate Filings
F4 | 20th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 19th of December 2024 Other Reports | ViewVerify | |
| 17th of December 2024 Other Reports | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.95) | Revenue Per Share | Quarterly Revenue Growth (0.70) | Return On Assets | Return On Equity |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.